-
AIDS Exclusive Interview | AMP Trial: Successes and Breakthroughs in HIV Prevention
01 IIDF: What are the key achievements of the AMP trials in the field of HIV prevention, and what is their significance for advancing HIV prevention strategies? Dr Yunda Huang:…
-
Interview with Dr. Michael Wang – Exciting Developments in Lymphoma Treatment!
In a recent Hematology Frontier interview, Dr. Michael Wang shared insights from the EHA Late Breaker Plenary Session, where the pivotal ECHO clinical trial was discussed. the study is leading to breakthroughs in lymphoma care. The promising combination of BR + Acalabrutinib shows potential to improve outcomes, especially for older patients. This could pave the…
-
AIDS Interview | HIV Vaccine: Where Are We Now, and What Does the Future Hold?
01 IIDF: How would you assess the current progress in HIV vaccine development? Are we nearing the realization of an effective and widely available HIV vaccine? Dr Sok: Yes, this…
-
New Advances in Renal Cancer Treatment
Excited to share this insightful talk with Dr. Liangyou Gu on tackling clear cell renal cell carcinoma with innovative approaches like neoadjuvant toripalimab. The future of kidney cancer treatment is evolving, and these advancements are offering real hope for better outcomes. Watch the video for key highlights!
-
Impact of Gut Microbiota on Patients with Decompensated Cirrhosis
The research included 75 participants: 45 with decompensated cirrhosis (LC group) and 30 healthy controls (C group). Patients in the LC group exhibited elevated serum levels of ALT, TBIL, PT,…
-
ESMO 2024 丨 Dr. Trevor Leong: The TOPGEAR study confirms that preoperative radiotherapy cannot prolong long-term survival in resectable gastric cancer
In the past, there has been ongoing debate about the therapeutic value of radiotherapy in resectable gastric cancer. The TOPGEAR study presented at the 2024 European Society for Medical Oncology (ESMO) Congress (September 13-17, Barcelona) evaluated the comparison between preoperative chemoradiotherapy and perioperative chemotherapy alone. Dr. Trevor Leong, the Principal Investigator from the University of…
-
Dr. Yelena Janjigian: The DESTINY-Gastric03 study confirms the therapeutic prospect of the T-DXd triple regimen in HER2-positive
The DESTINY-Gastric03 study (abstract number 14010), presented at the 2024 European Society for Medical Oncology (ESMO) Congress (September 13-17, Barcelona), evaluated the efficacy and safety of T-DXd combined with FP and anti-PD-1 as first-line treatment for adenocarcinoma of the esophagus, stomach, or gastroesophageal junction (GEJA). At the conference site, we specially invited the Principal Investigator,…
-
ESMO 2024丨 Dr. Benoit You interprets the TROPHAMET trial: 96% of low-risk gestational trophoblastic tumors can be eradicated
At the 2024 ESMO annual meeting, Benoit You from the Lyon Sud Hospital Center, France, presented the results of the phase I/II TROPHAMET trial (abstract number 711O) in the preferred oral report session and was interviewed by Oncology Frontier.
Connecting Medical Expertise through Media